An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.

摘要: The study goal was to characterize older chronic lymphocytic leukemia (CLL) patients and evaluate outcomes in those who initiated infused therapy. Patients 66 years of age the Surveillance, Epidemiology, End Results (SEER) program with a CLL diagnosis were matched their Medicare Part A B claims for long-term follow-up. Treatment patterns, survival after initiation therapy, both hematologic hospitalization assessed. There 6433 identified, 2040 received Treated categorized as receiving rituximab monotherapy (16%), plus chemotherapy (14%), alone (70%) based on initial 60 days infusion. Rituximab compared associated 25% lower risk overall mortality (95% confidence interval, 9%-38%). Restricting 70 did not change reduction chemotherapy. Hematologic interventions more common alone, but there no difference all-cause hospitalizations. These analyses, observational data, suggest that benefits therapy heterogeneous group are comparable demonstrated younger patients.